Literature DB >> 6487910

The limited utility of the dexamethasone suppression test for the diagnostic process in psychiatry.

M Berger, K M Pirke, P Doerr, J C Krieg, D von Zerssen.   

Abstract

In 231 psychiatric in-patients, the 1 mg or 1.5 mg DST with blood samples at 0900 h, 1600 h and 2300 h and a post-dexamethasone plasma cortisol threshold of greater than or equal to 5 micrograms/dl were tested for their differential diagnostic utility in clinical psychiatry. Neither test significantly separated endogenous depressed patients from patients with other depressive or non-depressive psychiatric disorders. Studies of the 1 mg or 1.5 mg DST in 75 healthy subjects revealed about 12% of cortisol non-suppressors, when a post-dexamethasone cortisol threshold of greater than or equal to 5 micrograms/dl was used. This seemed to be an unacceptably low specificity of the test in normal subjects. A threshold criterion of greater than or equal to 8 micrograms/dl, however, yielded only 2.7% of non-suppressed normal subjects. Analyses of the DST data of the psychiatric patients, using a cortisol threshold of greater than or equal to 8 micrograms/dl, also failed to reveal a significantly higher specificity of the DST for endogenous depression. However, it was demonstrated that intervening variables such as stress due to hospital admission, drug withdrawal, suicidal turmoil, weight loss, as well as a low dexamethasone plasma level, enhance the rate of abnormal DST results in psychiatric in-patients, regardless of their diagnostic classification.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487910     DOI: 10.1192/bjp.145.4.372

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  12 in total

1.  Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patients.

Authors:  S K Gupta; J C Ritchie; E H Ellinwood; K Wiedemann; F Holsboer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Glucocorticoid receptors in depression.

Authors:  B Harris; R Thomas
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-17

Review 3.  Psychoneuroendocrine research in depression. I. Hormone levels of different neuroendocrine axes and the dexamethasone suppression test.

Authors:  R Rupprecht; K P Lesch
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

4.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

5.  The dexamethasone suppression test in depressive and schizophrenic patients under controlled treatment conditions.

Authors:  H J Möller; W Kissling; P Bottermann
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

6.  Dexamethasone suppression test as a simple measure of stress?

Authors:  G W Mellsop; J D Hutton; J W Delahunt
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

7.  Judgement of the hypothalamic-pituitary-adrenocortical function in psychiatric patients by betamethasone-induced cortisol suppressibility.

Authors:  S Kasper; P Vecsei; P Richter; D Haack; K Diebold; L Katzinski
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

8.  [Dexamethasone suppression test: a biologic marker of endogenous depression?].

Authors:  M Berger; H E Klein
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

9.  Gonadal steroid and gonadotropin response to dexamethasone: a study in sexual dysfunction and normal controls.

Authors:  R Rupprecht; M Noder; E Jecht; W Schwarz; C Rupprecht; M Rupprecht; T Diepgen
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

10.  Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin.

Authors:  L von Knorring; B G Almay; J Häggendal; F Johansson; L Oreland; L Wetterberg
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.